Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) just unveiled an announcement.
BLASTID and Q-linea have announced a successful proof-of-concept for ultra-rapid diagnosis of bloodstream infections and sepsis, presented at the ADLM2025 Conference in Chicago. Their collaboration has resulted in technologies that significantly reduce the time to clinically actionable results from days to hours, potentially saving lives and reducing healthcare costs by providing faster and more accurate testing directly from whole blood samples.
More about Q-linea AB
Q-linea is a Swedish company specializing in rapid antimicrobial susceptibility testing (AST) systems, notably the ASTar platform, which aids in the treatment of bloodstream infections and sepsis by reducing the time to optimal antimicrobial therapies. BLASTID, a Boston-based Harvard spinout, develops diagnostic platforms for bloodstream infections and sepsis, utilizing its SPLENDID platform for pathogen isolation and antibiotic susceptibility testing.
Average Trading Volume: 26,183
Technical Sentiment Signal: Sell
Current Market Cap: SEK298.7M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.